Notably, there was a substantial increase in the number of perivascular CD8+ T cells and CD8+ granzyme B+ cells (Figure S4I-J), which may have contributed to the enhanced anti-tumor efficacy observed with the combined treatment. The gene discussed is CD8A; the disease is neoplasm.